Two firms raised Hinge Health’s price targets to $80 and $63 after reporting improved profitability and operational momentum.
Citizens raised its price target for Hinge Health Inc. (HNGE) to $80 from $65, citing accelerating top-line growth and expanding profitability margins. The firm highlighted strong invoicing trends and broader market integration across U.S. insurance networks and PBMs.
Canaccord also revised its outlook, lifting its target to $63 from $53 while maintaining a Buy rating. The firm noted slightly lower revenue upside than the prior quarter but emphasized improving operational efficiency and optimistic management guidance.
Both upgrades follow Hinge Health’s expansion into chronic ailment therapies and a robust distribution infrastructure supporting its hardware-assisted care model.